Tengzhou Central People's Hospital
12
4
4
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
33%
4 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
Role: collaborator
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
Role: collaborator
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Role: collaborator
Narrow Band Imaging Versus White Light for the Detection and Miss of Sessile Serrated Lesion
Role: collaborator
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
Role: collaborator
Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
Role: collaborator
Iodine-125 Seed Implantation Therapy for Locally Advanced Pancreatic Cancer
Role: collaborator
Clinical Efficacy of Stereotactic Radiotherapy and Microwave Ablation for Liver Metastases From Colorectal Cancer.
Role: collaborator
I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer
Role: collaborator
Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
Role: collaborator
Evaluation of Antithrombotic STrategies in STEMI Patients in China
Role: collaborator
Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty
Role: lead
All 12 trials loaded